Neal Freiman

Welcome to Stock of the Week, Dog of the Week, the segment where Toby and I pick one stock that kept its head and another that got April fooled.

I won the pre-show game of Dominion, so I get to go first.

And my Stock of the Week is Eli Lilly because it just entered the fray in what looks to be the next arena in the weight loss battles, a pill.

On Wednesday, the pharma giant said that the FDA approved its weight loss pill that will be sold under the brand name Foundeo.

Shares popped 6% as investors smelled another drug coming onto the market with blockbuster sales potential.

Foundeo isn't as powerful as its injectable cousin, Zepbound, which has been shown to consistently help people lose more than 20% of their body weight.

In clinical trials, Foundeo caused an average weight loss of about 12% for people with obesity after 72 weeks on the highest dose.

But what it lacks for in potency, it makes up for in convenience.

You can take Foundeo at any time of day, with food or without food.

It's that ease of use factor that has analysts projecting the pill could bring in $14.8 billion per year by 2030.

But Foundayo isn't the only GLP-1 pill in town.

Novo Nordisk, Eli Lilly's Danish rival, already has a weight loss pill on the market, the Wegovi pill, and it's selling like hotcakes.

Toby, welcome to the pill battles.

Well, the prices are the exact same.

The lowest doses of both drugs are going to cost $149.

for cash paying customers.

And that's thanks to an agreement that both companies, Eli Lilly and Novo Nordisk struck with the Trump administration last fall.

What is Novo?

How's Novo going to counter this?

Because, uh, if the price parity is the same, Eli Lilly's an American company and they have a little more, uh,